Rezolute, Inc. (NASDAQ:RZLT)
| Market Cap | 399.61M-44.4% |
| Revenue (ttm) | 0 |
| Net Income | -81.48M-11.6% |
| EPS | -0.82+29.3% |
| Shares Out | 96.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 752,858 |
| Open | 4.22 |
| Previous Close | 4.25 |
| Day's Range | 4.11 - 4.22 |
| 52-Week Range | 1.07 - 11.46 |
| Beta | 0.61 |
| Analysts | Buy |
| Price Target | 8.67(+108.92%) |
| Earnings Date | Sep 16, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About RZLT
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
$RZLT stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in RZLT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by RZLT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
RZLT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New RZLT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to RZLT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in RZLT
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $12.87M |
| IWMiShares Russell 2000 ETF | $8.79M |
| VXFVanguard Extended Market ETF | $4.77M |
| VTWOVanguard Russell 2000 ETF | $2.11M |
| SCHASchwab U.S. Small-Cap ETF | $1.74M |
| FESMFidelity Enhanced Small Cap ETF | $1.57M |
Estimated from each fund’s disclosed top holdings × AUM
RZLT Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from RZLT’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.